Neoadjuvant Chemotherapy for Oesophageal Cancer
Author Information
Author(s): Halliday Brian P, Skipworth Richard JE, Wall Lucy, Phillips Hamish A, Couper Graeme W, de Beaux Andrew C, Paterson-Brown Simon
Primary Institution: Royal Infirmary of Edinburgh
Hypothesis
Does neoadjuvant chemotherapy improve post-operative outcomes and survival in patients undergoing surgery for oesophageal cancer?
Conclusion
Neoadjuvant chemotherapy was associated with a significant reduction in post-operative inpatient mortality, but did not show statistically significant improvements in survival rates.
Supporting Evidence
- The NAC group had a lower in-hospital mortality rate compared to the non-NAC group.
- Two-year survival rates were higher in the NAC group, but not statistically significant.
- The NAC group was significantly younger than the non-NAC group.
Takeaway
Giving chemotherapy before surgery can help patients with oesophageal cancer recover better and live longer, but the results aren't always clear.
Methodology
Data from patients who underwent surgical resection for oesophageal cancer between April 2000 and July 2006 were collected and analyzed, comparing those who received neoadjuvant chemotherapy with those who did not.
Potential Biases
Potential selection bias due to the non-randomised nature of the study.
Limitations
The study was non-randomised and had a relatively small sample size, which may limit the generalizability of the findings.
Participant Demographics
The study included 167 patients, with 89 receiving neoadjuvant chemotherapy and 78 not receiving it; the NAC group was significantly younger.
Statistical Information
P-Value
0.045
Confidence Interval
95% CI = 390–1196
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website